Tumor M2-PK: A promising marker in the diagnosis of gastrointestinal cancer

Hardt, Philip D.; Ngoumou, Bona; Rupp, J; Schnell-Kretschmer, Henning; Kloer, H. U.

doi:10.1016/s0016-5085(00)83115-7

Cited by 27 publications

(32 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The mean values in T1, T2, T3 and T4 were 11.80, 31.87, 40.23 and 53 U/ml, respectively. This comes in agreement with (33) who found the mean value of T1, T2, T3 and T4 were 11.1, 23.8, 55.5 and 132.7 U/ml, respectively. The mean value of fecal tumor M2-PK level showed a statistically significant difference between different Duke's stages (P ˂ 0.05) in the present study with a statistically significant positive correlation.…”

Section: Fecal Tumor M2-pyruvate Kinase ™ (Schebo Test) For Colorectasupporting

confidence: 93%

“…The mean value of grade I was (6.25 U/ml), grade II (33.79 U/ml) and grade III (47.9 U/ml) (P ˂ 0.05). This was in agreement with (14,33) In the present study, the mean value of fecal tumor M2-PK level showed a statistically significant difference between different TNM stages (P ˂ 0.05) with a statistically significant positive correlation. The mean values in T1, T2, T3 and T4 were 11.80, 31.87, 40.23 and 53 U/ml, respectively.…”

Section: Fecal Tumor M2-pyruvate Kinase ™ (Schebo Test) For Colorectasupporting

confidence: 92%

See 1 more Smart Citation

Fecal Tumor M2-Pyruvate Kinase ™ (ScheBo Test) for Colorectal Cancer Detection in Adult Egyptians

Lashin¹

2017

IOSRJPBS

View full text Add to dashboard Cite

show abstract

Section: Fecal Tumor M2-pyruvate Kinase ™ (Schebo Test) For Colorectasupporting

confidence: 93%

Section: Fecal Tumor M2-pyruvate Kinase ™ (Schebo Test) For Colorectasupporting

confidence: 92%

Fecal Tumor M2-Pyruvate Kinase ™ (ScheBo Test) for Colorectal Cancer Detection in Adult Egyptians

Lashin¹

2017

IOSRJPBS

View full text Add to dashboard Cite

show abstract

“…An increase of Tumour M2-PK levels has also been measured in EDTA-plasma samples of patients with colorectal cancer (Hardt et al, 2000;Schulze, 2000;Schneider and Schulze, 2003). The sensitivity of the Tumour M2-PK EDTA-plasma test was lower (nonmetastasising cancer: 48%; metastasising cancer: 54%) than the Tumour M2-PK stool test (Dukes' A: 59%; Dukes' D: 90%).…”

Section: Discussionmentioning

confidence: 97%

“…Determinations of Tumour M2-PK in EDTA-plasma samples of patients with gastrointestinal tumours revealed an upregulation of Tumour M2-PK in oesophageal, gastric, colonic and rectal carcinomas (Hardt et al, 2000;Schulze, 2000;Schneider and Schulze, 2003). Recently, we noticed that Tumour M2-PK can be detected and quantified in the faeces of patients with gastrointestinal cancer (Hardt et al, 2003).…”

mentioning

confidence: 99%

Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer

et al. 2004

View full text Add to dashboard Cite

Proliferating cells, especially tumour cells, express a special isoenzyme of pyruvate kinase, termed M2-PK, which can occur in a tetrameric form with a high affinity to its substrate, phosphoenolpyruvate (PEP), and in a dimeric form with a low PEP affinity. In tumour cells, the dimeric form is usually predominant and is therefore termed Tumour M2-PK. The levels of Tumour M2-PK within tumours and in EDTA-plasma correlate with staging and the ability of the tumour cells to metastasise. Since most colorectal tumours grow intraluminally, it appeared interesting to determine whether Tumour M2-PK is detectable in the faeces of tumour patients. Stool samples were tested by ELISA from controls without colorectal cancer and colorectal cancer patients. Whereas Tumour M2-PK levels were low in the control group (mean value7s.e.m.: 3.370.4, n ¼ 144), they were high in the case of colorectal cancer (56.1715.3, n ¼ 60). At a cutoff value of 4 U ml À1 , the sensitivity was 73%. TNM and Dukes' classification of the tumours revealed a strong correlation between faecal Tumour M2-PK levels and staging. The determination of Tumour M2-PK in faeces provides a new promising screening tool for colorectal tumours.

show abstract

“…Tu-M2-PK levels are elevated in patients with breast, lung, renal and gastrointestinal cancer. 25,26,27,28 At least five previous published reports 26,29,32,33,34 have evaluated the role of Tu-M2-PK in the diagnosis of pancreatic cancer. Limitations inherent in several previous reports have been the lack of histologic confirmation of malignancy and sufficiently prolonged follow-up to assess survival.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic and Prognostic Value of Plasma Tumor M2 Pyruvate Kinase in Periampullary Cancer

Goonetilleke

Mason²,

Siriwardana³

et al. 2007

Pancreas

View full text Add to dashboard Cite

Use policyThe full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for personal research or study, educational, or not-for-prot purposes provided that:• a full bibliographic reference is made to the original source • a link is made to the metadata record in DRO • the full-text is not changed in any way The full-text must not be sold in any format or medium without the formal permission of the copyright holders.Please consult the full DRO policy for further details. 2 AbstractBackground: This prospective study examines the diagnostic and prognostic utility of tumor

show abstract

Tumor M2-PK: A promising marker in the diagnosis of gastrointestinal cancer

Cited by 27 publications

References 0 publications

Fecal Tumor M2-Pyruvate Kinase ™ (ScheBo Test) for Colorectal Cancer Detection in Adult Egyptians

Fecal Tumor M2-Pyruvate Kinase ™ (ScheBo Test) for Colorectal Cancer Detection in Adult Egyptians

Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer

Diagnostic and Prognostic Value of Plasma Tumor M2 Pyruvate Kinase in Periampullary Cancer

Contact Info

Product

Resources

About